XW043FB ICD-10-PCS Code: Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11

Related Codes

Same operation — other Body Part

Same table and root operation, differing only in the body part character.

XW033FB — Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11

Same operation — other Device / Substance / Technology

Same table and root operation, differing only in the device / substance / technology character.

XW0430B — Introduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11, XW0431B — Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11, XW043PB — Introduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11, XW043QB — Introduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11, XW043RB — Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11, XW043WB — Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11

Same operation — other Qualifier

Same table and root operation, differing only in the qualifier character.

XW043F3 — Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3, XW043F5 — Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5, XW043FA — Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10

Same procedure category (CCSR), other tables

AHRQ's Clinical Classifications Software Refined groups these ICD-10-PCS procedures with this one under Administration of therapeutic substances, NEC (Administration of Therapeutic Substances); listed here are the members in other PCS tables. Source: Clinical Classifications Software Refined (CCSR), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, November 2025.

3E0U3TZ — Introduction of Destructive Agent into Joints, Percutaneous Approach, 3E0U4GC — Introduction of Other Therapeutic Substance into Joints, Percutaneous Endoscopic Approach, 3E0V0GB — Introduction of Recombinant Bone Morphogenetic Protein into Bones, Open Approach, 3E0V0GC — Introduction of Other Therapeutic Substance into Bones, Open Approach, 3E0V3GB — Introduction of Recombinant Bone Morphogenetic Protein into Bones, Percutaneous Approach, 3E0V3GC — Introduction of Other Therapeutic Substance into Bones, Percutaneous Approach, 3E0V3TZ — Introduction of Destructive Agent into Bones, Percutaneous Approach, 3E0V4GC — Introduction of Other Therapeutic Substance into Bones, Percutaneous Endoscopic Approach, 3E0W3GC — Introduction of Other Therapeutic Substance into Lymphatics, Percutaneous Approach, 3E0W3TZ — Introduction of Destructive Agent into Lymphatics, Percutaneous Approach, 3E0X3GC — Introduction of Other Therapeutic Substance into Cranial Nerves, Percutaneous Approach, 3E0X3TZ — Introduction of Destructive Agent into Cranial Nerves, Percutaneous Approach, 3E0Y3GC — Introduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Approach, 3E0Y3SF — Introduction of Other Gas into Pericardial Cavity, Percutaneous Approach, 3E0Y3TZ — Introduction of Destructive Agent into Pericardial Cavity, Percutaneous Approach, 3E0Y4GC — Introduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Endoscopic Approach, 3E0Y7SF — Introduction of Other Gas into Pericardial Cavity, Via Natural or Artificial Opening, XY0VX83 — Extracorporeal Introduction of Endothelial Damage Inhibitor to Vein Graft, New Technology Group 3, XY0YX28 — Extracorporeal Introduction of Taurolidine Anti-infective and Heparin Anticoagulant, New Technology Group 8, XY0YX37 — Extracorporeal Introduction of Nafamostat Anticoagulant, New Technology Group 7, +213 more

Contextual Map

Every relationship of XW043FB in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.

Run XW043FB with these 5 related codes in Claim Check

PCS table

• XW0[PCS table]— CMS ICD-10-PCS tables
• New Technology — Section: New Technology[Section]: “New Technology”— CMS ICD-10-PCS tables
• Anatomical Regions — Body System: Anatomical Regions[Body System]: “Anatomical Regions”— CMS ICD-10-PCS tables
• Introduction — Operation: Introduction[Operation]: “Introduction”— CMS ICD-10-PCS tables

MS-DRG participation

• DRG 018 — CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL AND OTHER IMMUNOTHERAPIES[MS-DRG]: “CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL AND OTHER IMMUNOTHERAPIES — Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies (MDC PRE)”— CMS MS-DRG Definitions Manual (Appendix E) · FY2027

Clinical classification (CCSR)

• ADM021 — Administration of therapeutic substances, NEC[CCSR category]: “Administration of therapeutic substances, NEC — Administration of Therapeutic Substances”— AHRQ CCSR for ICD-10-PCS Procedures (HCUP) · v2026.1

MDC crossing · diagnoses (1333)

• Pre-MDC[MDC crossing]: “Pre-MDC — the grouper's crossing between diagnoses and procedures: a principal diagnosis sets the MDC, and same-MDC procedures move the stay to its surgical DRGs.”— CMS MS-DRG Definitions Manual · FY2027
• A36.0 — Pharyngeal diphtheria[Same-MDC diagnosis]: “Pharyngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.”— CMS MS-DRG Definitions Manual (Appendix B) · FY2027
• A36.1 — Nasopharyngeal diphtheria[Same-MDC diagnosis]: “Nasopharyngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.”— CMS MS-DRG Definitions Manual (Appendix B) · FY2027
• A36.2 — Laryngeal diphtheria[Same-MDC diagnosis]: “Laryngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.”— CMS MS-DRG Definitions Manual (Appendix B) · FY2027
• A54.5 — Gonococcal pharyngitis[Same-MDC diagnosis]: “Gonococcal pharyngitis — grouped in MDC PRE, the diagnosis side of this code's crossing.”— CMS MS-DRG Definitions Manual (Appendix B) · FY2027
• A56.4 — Chlamydial infection of pharynx[Same-MDC diagnosis]: “Chlamydial infection of pharynx — grouped in MDC PRE, the diagnosis side of this code's crossing.”— CMS MS-DRG Definitions Manual (Appendix B) · FY2027
• and 1328 more

Nearest codes

• XW033FB — Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11[One axis away]— CMS ICD-10-PCS tables
• XW0430B — Introduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11[One axis away]— CMS ICD-10-PCS tables
• XW0431B — Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11[One axis away]— CMS ICD-10-PCS tables
• XW043F3 — Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3[One axis away]— CMS ICD-10-PCS tables
• XW043F5 — Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
• XW043FA — Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10[One axis away]— CMS ICD-10-PCS tables
• XW043PB — Introduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11[One axis away]— CMS ICD-10-PCS tables
• XW043QB — Introduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11[One axis away]— CMS ICD-10-PCS tables

Change history

• FY2026 — Added to the code set[Change history]— CMS release files (code change ledger) · icd10pcs-fy2026oct